MyFinsight
Home
Blog
About
Contact
Download
Download image
Depreciation and
amortization
$223,572K
Net income (loss)
$127,933K
Inventory provision
$85,962K
Stock-based compensation
$31,953K
Loss on refinancing
-$31,365K
Intangible asset
impairment charges
$22,784K
Amortization of debt issuance
costs and discount
$22,431K
Accounts payable,
accrued expenses and...
$21,321K
Other operating
charges and credits, net
-$4,732K
Reclassification of cash flow
hedge
-$1,229K
Related party payables
$931K
Net cash provided by
operating activities
$339,992K
Canceled cashflow
$234,221K
Net increase in
cash, cash...
$194,519K
Canceled cashflow
$145,473K
Trade accounts
receivable, net
$120,566K
Inventories
$87,026K
Prepaid expenses, other
current assets and other...
$19,163K
Unrealized foreign
currency (gain) loss
$7,453K
Related party
receivables
$13K
Proceeds from sale of
property, plant,...
$2,094K
Proceeds from issuance of
debt
$2,694,750K
Borrowings on revolving
credit facility
$218,000K
Proceeds from alliance
party
$6,367K
Proceeds from exercise of
stock options
$1,960K
Net cash used in
investing activities
-$112,263K
Net cash used in
financing activities
-$31,530K
Effect of foreign
exchange rate on cash
-$1,680K
Canceled cashflow
$2,094K
Canceled cashflow
$2,921,077K
Purchases of property,
plant and equipment
$70,063K
Deposits for future
acquisition of property,...
$28,780K
Acquisition of intangible
assets
$15,514K
Payments of principal on
debt, revolving...
-$2,811,508K
Payments of deferred
financing, refinancing...
$74,973K
Tax and other
distributions to...
$43,848K
Employee payroll tax
withholding on restricted...
$22,278K
Back
Back
Cash Flow
source: myfinsight.com
Amneal Pharmaceuticals, Inc. (AMRX)
Amneal Pharmaceuticals, Inc. (AMRX)